A pharmacological approach for selection of potential anticancer agents

Alternatives to Laboratory Animals

Volumn 32, Issue SUPPL. 2, 2004, Pages 41-48

  Double, John A ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Anticancer agents; Hollow fibre system; Pharmacology; Reduction; Refinement

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL MODEL; ANIMAL TESTING REDUCTION; ANIMAL TESTING REFINEMENT; ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CARCINOGENESIS; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DESIGN; DRUG FORMULATION; DRUG PENETRATION; DRUG RESEARCH; DRUG TARGETING; EXPERIMENTAL ANIMAL; HOLLOW FIBER SYSTEM; MAXIMUM TOLERATED DOSE; METHODOLOGY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANIMALIA;

EID: 8744224666     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119290403202s09     Document Type: Conference Paper

References (10)

1. Muggia, F.M. (1987). Closing the loop: providing a feedback on drug development. Cancer Treatment Reports 71, 1-2.
2. Boyd, M.R. (1989). Status of the NCI preclinical anti-tumour drug discovery screen. In Cancer: Principles and Practice of Oncology Update, 3rd edn (ed. V.T. DeVita Jr, S. Hellman & S.A. Rosenberg), pp. 1-12. Philadelphia, PA, USA: Lippincott.
3. Double, J.A. & Bibby, M.C. (1989). Therapeutic index: a vital component in selection of anticancer agents for clinical trial. Journal of the National Cancer Institute 81, 988-994.
4. Double, J.A. (1968). Extracellular factors influencing the response of tumours to chemotherapeutic agents. In Recent Results in Cancer Research: Scientific Basis of Cancer Chemotherapy, Vol. 21 (ed. G. Mathé), pp. 18-25. New York, NY, USA: Springer-Verlag.
5. Matthew, A.M., Phillips, R.M. & Bibby, M.C. (1996). Optimisation of EO9 activity in human tumour xenografts. Annals of Oncology 7, Suppl. 1, 131.
6. Boyd, M.R. & Paull, K.D. (1995). Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Development Research 34, 91-109.
7. Hollingshead, M.G., Alley, M.C., Camalier, R.F., Abbott, B.J., Mayo, J.G., Malspeis, L. & Grever, M.R. (1995). In vivo cultivation of tumour cells in hollow fibres. Life Sciences 57, 131-141.
8. Workman, P., Twentyman, P., Balkwill, F., Balmain, A., Chaplin, D., Double, J., Embleton, J., Newell, D., Raymond, R., Stables, J., Stephens, T. & Wallace, J. (1998). United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). British Journal of Cancer 77, 1-10.
9. Grosios, K., McGown, A.T., Pettit, G.R. & Bibby, M.C. (1997). In vitro evaluation of combretastatin A4 and its analogue. British Journal of Cancer 75, Suppl. 1, 20.
10. Phillips, R.M., Pearce, J., Loadman, P.M., Bibby, M.C., Cooper, P.A., Swaine, D.J. & Double, J.A. (1998). Angiogenesis in the hollow fiber tumor model influences drug delivery to tumour cells: implication for anticancer drug screening programmes. Cancer Research 58, 5263-5266.